Back to search results

Early Detection of Pancreatic Cancer in Patients with Pancreatic Cysts

This study aims to find better ways to detect pancreatic ductal adenocarcinoma (PDAC), a type of pancreatic cancer, early in people who have pancreatic cysts. Researchers are testing if a combination of special imaging scans and blood tests can effectively identify PDAC. The imaging tests include an ImmunoPET scan using 89Zr-DFO-HuMab-5B1 and an HP MRI (hyperpolarized pyruvate magnetic resonance imaging) scan. Blood tests will also be collected. The main goal is to see how well the ImmunoPET scan can identify the presence or absence of PDAC. You may be eligible if you are over 18, have a high-risk pancreatic cyst needing surgery, and can give informed consent. The study is currently unclear on its recruitment status.

Study design
This is an observational study planning to enroll 25 participants. It is not specified if it is randomized or blinded.
What's involved
If you choose, you would undergo ImmunoPET and HP MRI scans before surgery. Blood samples will be drawn within 6 weeks of surgery and annually for post-operative care.
Compensation
Not stated in the trial record.
Follow-up
The study will measure the sensitivity of ImmunoPET to identify adenocarcinoma for up to 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06305728

Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms

Recruiting
Not specifiedAges 18+Observational
Memorial Sloan Kettering Cancer Center
~25 participants
Updated 2026-08-25 on ClinicalTrials.gov
What's tested:89Zr-DFO-HuMab-5B1 immunoPETHP MRIBlood assay

At a glance

Recruiting sites
7 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Sensitivity of ImmunoPET to identify presence or absence of adenocarcinoma
Measured over up to 1 year

Conditions

Pancreatic Cyst

Explore related trials

Pancreatic Cyst

Where it's being run

8 sites across 2 states
New York5
New Jersey3

Study leadership

  • Kevin Soares, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Kevin Soares, MD
[email protected]
212-639-3195
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Men and women aged \>18 years
Pancreatic cystic neoplasm deemed to be high risk and requiring surgical resection
Able to provide informed consent

Exclusion

Pathologic evidence of pancreatic cancer
Pregnant or breast-feeding patients
Refusal or inability to tolerate scan (eg anxiety or claustrophobia)
Inability to lay flat or meet the standard requirements of traditional MRI
Hepatic function from assays obtained within 6 weeks prior to the study enrollment. For each patient, the upper limit of normal (ULN) value for a particular assay will be defined by the normal reference values of the laboratory that performed the assay
Renal function with Creatinine \> 1.5 x ULN or creatinine clearance \< 60 mL/min, from assays obtained within 6 weeks prior to study enrollment
Cardiac: congestive heart failure with New York Heart Association (NYHA) status ≥2, poorly controlled hypertension, a history of clinically significant EKG abnormalities, or myocardial infarction within 6 months of study enrollment.

What this trial measures

  • Sensitivity of ImmunoPET to identify presence or absence of adenocarcinomaup to 1 year

    Assess preliminary sensitivity and specificity if the immunoPET is able to identify the presence or absence of adenocarcinoma or high-grade dysplasia in participants who are scheduled to undergo surgical resection.